Abstracts tagged "juvenile idiopathic arthritis (JIA)"

Abstract Number: 407 • 2016 ACR/ARHP Annual Meeting
Comparability of Proxy, Adolescent and Adult Measures of Functional Ability in Adolescents with JIA
Stephanie J.W.Shoop^1,2, Kimme L. Hyrich^3,4, Suzanne M.M. Verstappen⁴, Wendy Thomson^5,6, Janet E. McDonagh⁷ and CAPS, ¹The University of Manchester, Arthritis Research UK Centre for Epidemiology, Manchester, United Kingdom, ²Central Manchester University Hospitals NHS Foundation Trust and University of Manchester Partnership, NIHR Manchester Musculoskeletal Biomedical Research Unit, Manchester, United Kingdom, ³Arthritis Research UK, Centre for Epidemiology, Centre for Musculoskeletal Research, Manchester Academic Health Sciences Centre, The University of Manchester, Manchester, United Kingdom, ⁴Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom, ⁵Arthritis Research UK Centre for Genetics and Genomics,The University of Manchester, Manchester, United Kingdom, ⁶NIHR Manchester Musculoskeletal Biomedical Research Unit, Arthritis Research UK Centre for Genetics and Genomics, Centre for Musculoskeletal Research, Institute of Inflammation and Repair, The University of Manchester, Manchester, United Kingdom, ⁷Faculty of Medical and Human Sciences, Centre for MSK Research, Manchester, United Kingdom
Background/Purpose: It is unclear which tool should measure functional ability in adolescents with JIA. The proxy-completed Childhood Health Assessment Questionnaire (P-CHAQ) is completed on the…
Abstract Number: 3115 • 2016 ACR/ARHP Annual Meeting
Reconsidering the Juvenile Idiopathic Arthritis Core Set: How Patients and Caregivers Define Disease Activity
Jennifer R. Horonjeff¹, Susan Thornhill², Daniel B. Horton³, Jennifer N. Stinson⁴, Anjali Fortna⁵, Stephanie Luca⁶, Arlene Vinci⁷, Laura C. Marrow⁸, Emily L. Creek⁷, Meredith Riebschleger⁹, Alessandro Consolaro¹⁰, Jane Munro¹¹, Vibeke Strand¹², Clifton Bingham III¹³ and Esi Morgan¹⁴, ¹Rheumatology, Columbia University Medical Center, New York, NY, ²Thornhill Associates, Hermosa Beach, CA, ³Pediatrics, Division of Pediatric Rheumatology, Rutgers Robert Wood Johnson Medical School, Rutgers Biomedical and Health Sciences, New Brunswick, NJ, ⁴Anesthesia and Pain Medicine, The Hospital for Sick Children, Toronto, ON, Canada, ⁵Columbia University Medical Center, New York, NY, ⁶The Hospital for Sick Children, Toronto, ON, Canada, ⁷Consumer Health, Arthritis Foundation, Atlanta, GA, ⁸Arthritis Foundation, Atlanta, GA, ⁹Pediatric Rheumatology & Health Services Research, University of Michigan, Ann Arbor, MI, ¹⁰Pediatria II - Reumatologia, PRINTO, Istituto Giannina Gaslini, Genoa, Italy, ¹¹Rheumatology, Royal Children's Hospital, Parkville, Australia, ¹²Stanford University School of Medicine, Palo Alto, CA, ¹³Divisions of Rheumatology and Allergy, Department of Medicine, Johns Hopkins University, Johns Hopkins University, Baltimore, MD, ¹⁴Pediatric Rheumatology, Cincinnati Children's Hospital, Cincinnati, OH
Background/Purpose: The current JIA Core Set (ACR Pediatric 30) contains items that should be assessed in clinical trials for children with JIA. It was developed…
Abstract Number: 410 • 2016 ACR/ARHP Annual Meeting
Sleep and Its Relationship to Pain and Disease Activity in Turkish Children and Adolescent with Juvenile Idiopathic Arthritis
Ela Tarakci¹, Saime Nilay Baydogan¹, Kenan Barut², Amra Adrovic², Sezgin Sahin² and Ozgur Kasapcopur³, ¹Istanbul University, Faculty of Health Science, Division of Physiotherapy and Rehabilitation, Istanbul, Turkey, ²Pediatric Rheumatology, Istanbul University, Cerrahpasa Medical School, Department of Pediatric Rheumatology, Istanbul, Turkey, ³Department of Pediatric Rheumatology, Istanbul University, Cerrahpasa Medical School, Department of Pediatric Rheumatology, Istanbul, Turkey
Background/Purpose: Juvenile idiopathic arthritis is a broad term that describes a clinically heterogeneous group of arthritis of unknown cause, which begin before 16 years of…
Abstract Number: 411 • 2016 ACR/ARHP Annual Meeting
Evaluating Levels of Activity and Health-Related Quality of Life in a Cohort of Youth Athletes with Juvenile Idiopathic Arthritis
Tommy Gerschman¹, Jordan Raugust², Julia Brooks³, Nicole Johnson¹, Nadia Luca¹, Rebeka Stevenson¹, Heinrike Schmeling⁴, Paivi Miettunen¹ and Susanne Benseler¹, ¹Pediatrics, University of Calgary, Calgary, AB, Canada, ²Department of Pediatrics, University of Calgary, Calgary, AB, Canada, ³Pediatrics, Alberta Children's Hospital, Calgary, AB, Canada, ⁴Paediatrics, University of Calgary, Calgary, AB, Canada
Background/Purpose: Children with JIA are increasingly being encouraged to be physically active and are participating in organized and competitive sports as youth athletes. These youth…
Abstract Number: 416 • 2016 ACR/ARHP Annual Meeting
Uveitis Associated to Polyarticular Juvenile Idiopathic Arthritis
Ivan Foeldvari¹, Nicolino Ruperto¹, Daniel J Lovell², Gerd Horneff¹, Hans-Iko Huppertz³, Pierre Quartier⁴, Gabriele Simonini¹, Mareike Bereswill⁵, Jasmina Kalabic⁵, Alberto Martini¹ and Hermine I. Brunner², ¹PRINTO-IRCCS, Genova, Italy, ²PRCSG, Cincinnati, OH, ³PRINTO-IRCCS, Genoa, Italy, ⁴Hôpital Necker-Enfants Malades, Paris, France, ⁵AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany
Background/Purpose: Approximately 10-15% of patients (pts) with juvenile idiopathic arthritis (JIA) experience comorbid uveitis. The objective of this study is to explore events of uveitis and…
Abstract Number: 417 • 2016 ACR/ARHP Annual Meeting
Use of Tumor Necrosis Factor-α Inhibitors in Pediatric HLA-B27-Associated Uveitis
Bessie Frias¹, Courtney McCracken², Kirsten Jenkins³, Janet Figueroa⁴, Anna Tramposch¹, Steven Yeh⁵, Purnima Patel⁴, Carolyn Drews-Botsch⁶, Sampath Prahalad^7,8 and Sheila Angeles-Han^2,7, ¹Emory University, Atlanta, GA, ²Pediatrics, Emory University School of Medicine, Atlanta, GA, ³Emory University School of Medicine and Children's Healthcare of Atlanta, Atlanta, GA, ⁴Emory University School of Medicine, Atlanta, GA, ⁵Ophthalmology, Emory University School of Medicine, Atlanta, GA, ⁶Epidemiology, Emory University School of Public Health, Atlanta, GA, ⁷Children's Healthcare of Atlanta, Atlanta, GA, ⁸Pediatric Rheumatology, Emory University School of Medicine, Atlanta, GA
Background/Purpose: Pediatric HLA-B27-associated uveitis is a common form of non-infectious uveitis (NIU) that can lead to ocular complications and vision loss. Methotrexate (MTX) is the…
Abstract Number: 1470 • 2015 ACR/ARHP Annual Meeting
A Population-Based Study of Outcomes of Patients with Juvenile Idiopathic Arthritis (JIA) Compared to Non-JIA Subjects
Megan L. Krause¹, J.A. Zamora-Legoff², Cynthia S. Crowson³, Thomas Mason II¹, Theresa Wampler Muskardin² and Eric L. Matteson⁴, ¹Rheumatology, Mayo Clinic, Rochester, MN, ²Division of Rheumatology, Mayo Clinic, Rochester, MN, ³Health Sciences Research, Mayo Clinic, Rochester, MN, ⁴Division of Rheumatology, Department of Internal Medicine and Department of Health Sciences Research, Mayo Clinic, Rochester, MN
Background/Purpose: The impact of juvenile idiopathic arthritis (JIA) is not confined to joint involvement in children but rather widespread effects extending to adulthood. This study…
Abstract Number: 3245 • 2015 ACR/ARHP Annual Meeting
Factors Associated with Physical Activity in Older Children with Juvenile Idiopathic Arthritis
Jennifer R. Horonjeff¹, Shira Weiner², Susan Klepper³, Ali Sheikhzadeh², Philip Kahn⁴ and Sherri Weiser², ¹Ergonomics and Biomechanics, New York University, New York, NY, ²Orthopedics, New York University, New York, NY, ³Physical Therapy Program, Columbia University, New York, NY, ⁴Pediatric Rheumatology, New York University, New York, NY
Background/Purpose: The purpose of this study was to examine factors associated with physical activity (PA) in children with JIA. PA is important for the physical,…
Abstract Number: 1475 • 2015 ACR/ARHP Annual Meeting
Fatigue, Quality of SLEEP and PAIN in Children with Juvenile Idiopathic Arthritis
Ela Tarakci¹, Saime Nilay Baydogan², Kenan Barut³ and Ozgur Kasapcopur⁴, ¹Division of Physiotherapy and Rehabilitation, Faculty of Health Science, Istanbul University,, Associate Professor, Istanbul, Turkey, ²Division of Physiotherapy and Rehabilitation, Faculty of Health Science, Istanbul University,, Assistant Professor, Istanbul, Turkey, ³Pediatric Rheumatology, Istanbul University, Cerrahpasa Medical Faculty, Istanbul, Turkey, ⁴Istanbul University, Cerrahpasa Medical School, Department of Pediatric Rheumatology, Professor of Pediatric Rheumatology, Istanbul, Turkey
Background/Purpose: Juvenile Idiopathic Arthritis (JIA) is one of the most common rheumatic diseases in childhood, affecting at least 1 in 1000 children (1). Children with…
Abstract Number: 1479 • 2015 ACR/ARHP Annual Meeting
Qualitative Assessment of Patient Important Long-Term Outcomes in Juvenile Idiopathic Arthritis
Melissa L. Mannion¹, Michelle Williams², Nataliya Ivankova³, Gerald McGwin Jr.⁴, Kenneth G. Saag⁵ and Timothy Beukelman⁶, ¹Pediatrics, University of Alabama at Birmingham, Birmingham, AL, ²School of Public Health, University of Alabama at Birmingham, Birmingham, AL, ³Health Services Administration, University of Alabama at Birmingham, Birmingham, AL, ⁴Epidemiology, University of Alabama at Birmingham, Birmingham, AL, ⁵University of Alabama at Birmingham, Birmingham, AL, ⁶Pediatric Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: The aim of this study was to identify and characterize the factors that JIA patients in young adulthood use to define a successful disease…
Abstract Number: 1482 • 2015 ACR/ARHP Annual Meeting
Temporomandibular Pain in Patients with Juvenile Idiopathic Arthritis
Peter Stoustrup¹, Marinka Twilt², Bernd Koos³, N Tzaribachev⁴, Troels Herlin⁵, Thomas Klit Pedersen⁶ and Lynn R. Spiegel⁷, ¹Section of Orthodontics, University of Aarhus, Aarhus C, Denmark, ²Pediatric Rheumatology, Aarhus University Hospital, Aarhus, Denmark, ³Orthodontics, University of Rostock, Rostock, Germany, ⁴Pediatric Rheumatology, PRI - Pediatric Rheumatology Research Institute, Bad Bramstedt, Germany, ⁵Pediatric Rheumatology Clinic, Department of Pediatrics, Aarhus University Hospital, Aarhus, Denmark, ⁶orthodontics, Aarhus University Hospital/Dental school, Aarhus, Denmark, ⁷Rheumatology/Pediatrics, The Hospital for Sick Children, Toronto, ON, Canada
Background/Purpose: Joint pain is a primary symptom in Juvenile Idiopathic Arthritis (JIA). Experience of pain has been shown to be a significant predictor of impaired…
Abstract Number: 2026 • 2015 ACR/ARHP Annual Meeting
A Novel Technique for Quantifying Synovial Enhancement of Temporomandibular Joints from Mris of Patients with Juvenile Idiopathic Arthritis
Cory M. Resnick¹, Pouya Vakilian², Micheal Breen³, David Zurakowski⁴, Zachary S. Peacock⁵ and Leonard B. Kaban⁵, ¹Plastics and Oral Surgery, Boston Children's Hospital, boston, MA, ²Harvard School of Dental Medicine, Boston, MA, ³Radiology, Boston Children's Hospital, Boston, MA, ⁴Departments of Anesthesia and Surgery, Boston Children’s Hospital, Boston, MA, ⁵Oral and Maxillofacial Surgery, Massachusetts General Hospital, Boston, MA
Background/Purpose: Juvenile Idiopathic Arthritis (JIA) commonly affects the temporomandibular joints (TMJ) and may cause growth disturbance, functional limitation and facial deformity. Early diagnosis and management…
Abstract Number: 2171 • 2015 ACR/ARHP Annual Meeting
A Comparison of Maternal Outcomes in Women with and without Juvenile Idiopathic Arthritis
Debbie Ehrmann Feldman¹, Sasha Bernatsky², Evelyne Vinet³, Ciarán M. Duffy⁴, Elizabeth Hazel⁵, Garbis Meshefedjian⁶, Marie-Pierre Sylvestre⁷ and Anick Bérard¹, ¹Université de Montréal, Montréal, QC, Canada, ²Rheum/Clin. Epid., McGill MUHC/RVH, Montreal, QC, Canada, ³McGill University Health Centre, Montreal, QC, Canada, ⁴Children's Hospital of Eastern Ontario and University of Ottawa, Ottawa, ON, Canada, ⁵Rhematology, McGill University Health Centre, Montreal, QC, Canada, ⁶Public Health Department of Montreal, Montreal, QC, Canada, ⁷Université de Montréal, Montreal, QC, Canada
Background/Purpose: Although there is a higher frequency of adverse maternal outcomes in mother with rheumatoid arthritis, little is known regarding mothers with juvenile idiopathic arthritis…
Abstract Number: 2416 • 2015 ACR/ARHP Annual Meeting
Pharmacokinetics, Safety, and Tolerability of Tofacitinib in Pediatric Patients from Six to Less Than Eighteen Years of Age with Juvenile Idiopathic Arthritis
Hermine I. Brunner¹, Nicolino Ruperto², Nikolay Tzaribachev³, Zbigniew Zuber⁴, Elena Koskova⁵, Ivan Foeldvari⁶, Eizbieta Smolewska⁷, Gerd Horneff⁸, Charles Mebus⁹, Umberto Conte¹⁰, Rong Wang⁹, Christine Alvey⁹, Manisha Lamba⁹, Anasuya Hazra¹¹, Daniel Lovell¹² and Alberto Martini¹³, ¹Pediatric Rheumatology Collaborative Study Group, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Istituto G. Gaslini, Pediatria II, PRINTO, Genoa, Italy, ³Pediatric Rheumatology, Bad Bramstedt, Germany, ⁴St Louis Children’s Hospital ODS Rheumatology and Neurology, Krakow, Poland, ⁵Institute of Rheumatic Diseases, Piestany, Slovakia, ⁶Hamburger Zentrum für Kinder-und Jugendrheumatologie, Hamburg, Germany, ⁷Department of Pediatric Cardiology and Rheumatology, Medical University of Lodz, Lodz, Poland, ⁸Asklepios Klinik Sankt Augustin GmbH, Sankt Augustin, Germany, ⁹Pfizer Inc, Groton, CT, ¹⁰Pfizer Inc, New York, NY, ¹¹Pfizer Inc, Collegeville, PA, ¹²Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ¹³Istituto G. Gaslini, Pediatria II, PRINTO, and University of Genoa, Genoa, Italy
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of adult patients with rheumatoid arthritis (RA). We report the pharmacokinetics (PK), safety and…
Abstract Number: 2423 • 2015 ACR/ARHP Annual Meeting
An Open-Label Extension Study to Assess the Long-Term Safety and Clinical Benefit of Etanercept on Children and Adolescents with Extended Oligoarticular Juvenile Idiopathic Arthritis, Enthesitis-Related Arthritis, or Psoriatic Arthritis: A 4-Year Update
Nicolino Ruperto¹, Tamas Constantin², Ivan Foeldvari³, Jelena Vojinovic⁴, Gerd Horneff⁵, Rubén Burgos-Vargas⁶, Irina Nikishina⁷, Jonathan Akikusa⁸, Tadej Avcin⁹, Jeffrey Chaitow¹⁰, Elena Koskova¹¹, Bernard R. Lauwerys¹², Inmaculada Calvo-Penedes¹³, Berit Flato¹⁴, Maria Luz Gamir Gamir¹⁵, Hans-Iko Huppertz¹⁶, Juan Jose Jaller Raad¹⁷, Katerina Jarosova¹⁸, Jordi Anton¹⁹, Marie Macku²⁰, William Jose Otero Escalante²¹, Lidia Rutkowska-Sak²², Ralf Trauzeddel²³, Carine Wouters²⁴, Ronald Pedersen²⁵, Sameer Kotak²⁶, Jack F Bukowski²⁷, Tina Hinnershitz²⁸, Bonnie Vlahos²⁹ and Alberto Martini³⁰, ¹Pediatria II, PRINTO, Istituto G. Gaslini, Universita' di Genova, Genova, Italy, ²Semmelweis University, Budapest, Hungary, ³Hamburg Centre for Child and Adolescent Rheumatology, Hamburg, Germany, ⁴Faculty of Medicine, University of Nis, Nis, Serbia, ⁵Asklepios Clinic Sankt Augustin, Sankt Augustin, Germany, ⁶Rheumatology, Hospital General de Mexico, Mexico city, Mexico, ⁷V.A. Nasonova Research Institute of Rheumatology, Moscow, Russia, ⁸Rheumatology, Royal Children's Hospital, Melbourne, Australia, ⁹Allergology, Rheumatology and Clinical Immunology, University Medical Center Ljubljana, Ljubljana, Slovenia, ¹⁰The Sydney Children's Hospital Network, Sydney, Australia, ¹¹National Institute of Rheumatic Diseases, Piestany, Slovakia, ¹²Cliniques Universitaires Saint-Luc, Brussels, Belgium, ¹³Hospital Universitario y Piltecnico La Fe, Valencia, Spain, ¹⁴Oslo University Hospital, Oslo, Norway, ¹⁵Rheumatology, Hospital Ramon y Cajal Unidad de Reumatologia Pediatrica, Madrid, Spain, ¹⁶Klinikum Bremen-Mitte, Prof.-Hess-Kinderklinik, Bremen, Germany, ¹⁷Centro de Reumatologia y Ortopedia, Barranquilla, Colombia, ¹⁸Revmatologicky ustav, Prague, Czech Republic, ¹⁹Unitat de Reumatologia Pediàtrica, Hospital Sant Joan de Déu, Barcelona, Spain, ²⁰1, Facutly Children's Hospital Brno, Brno, Czech Republic, ²¹Servimed S.A.S, Santander, Colombia, ²²Instytut Reumatologii, Klinika i Poliklinika Reumatologii Wieku Rozwojowego, Warszawa, Poland, ²³HELIOS Klinikum Berlin-Buch Klinik fuer Kinder- und Jugendmedizin, Berlin, Germany, ²⁴UZ Leuven, Leuven, Belgium, ²⁵Department of Biostatistics, Pfizer, Collegeville, PA, ²⁶Global Health and Value, Pfizer, New York, NY, ²⁷Pfizer, Collegeville, PA, ²⁸Specialty Care MDG, Pfizer, Collegeville, PA, ²⁹GIPB - Clinical Sciences, Pfizer, Collegeville, PA, ³⁰Istituto G. Gaslini, Universita' di Genova, Genova, Italy
Background/Purpose: A Phase 3b, open-label, multicenter study (CLIPPER; NCT00962741) demonstrated the efficacy of etanercept (ETN) in subjects with the extended oligoarticular (eo), enthesitis-related (ERA), and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.